- Home
- HEQ vs ALEC Comparison
HEQ vs ALEC Comparison
Compare HEQ & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- ALEC
- Stock Information
- Founded
- HEQ 2011
- ALEC 2013
- Country
- HEQ United States
- ALEC United States
- Employees
- HEQ N/A
- ALEC N/A
- Industry
- HEQ Investment Managers
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HEQ Finance
- ALEC Health Care
- Exchange
- HEQ Nasdaq
- ALEC Nasdaq
- Market Cap
- HEQ 127.0M
- ALEC 124.0M
- IPO Year
- HEQ N/A
- ALEC 2019
- Fundamental
- Price
- HEQ $10.56
- ALEC $1.55
- Analyst Decision
- HEQ
- ALEC Buy
- Analyst Count
- HEQ 0
- ALEC 7
- Target Price
- HEQ N/A
- ALEC $4.70
- AVG Volume (30 Days)
- HEQ 43.1K
- ALEC 1.2M
- Earning Date
- HEQ 01-01-0001
- ALEC 05-08-2025
- Dividend Yield
- HEQ 9.78%
- ALEC N/A
- EPS Growth
- HEQ N/A
- ALEC N/A
- EPS
- HEQ N/A
- ALEC N/A
- Revenue
- HEQ N/A
- ALEC $88,339,000.00
- Revenue This Year
- HEQ N/A
- ALEC N/A
- Revenue Next Year
- HEQ N/A
- ALEC $392.45
- P/E Ratio
- HEQ N/A
- ALEC N/A
- Revenue Growth
- HEQ N/A
- ALEC N/A
- 52 Week Low
- HEQ $9.08
- ALEC $0.87
- 52 Week High
- HEQ $11.84
- ALEC $6.78
- Technical
- Relative Strength Index (RSI)
- HEQ 59.89
- ALEC 64.93
- Support Level
- HEQ $10.50
- ALEC $1.28
- Resistance Level
- HEQ $10.62
- ALEC $1.46
- Average True Range (ATR)
- HEQ 0.10
- ALEC 0.12
- MACD
- HEQ -0.01
- ALEC 0.03
- Stochastic Oscillator
- HEQ 48.86
- ALEC 96.43
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.